Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Subsidiary of Sino Biopharmaceutical (1177) · China

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

February 2026Filing acceptedFHND9041NMPA accepted the FHND9041 NDA for first-line EGFR 19del NSCLC
CN, NMPA · Source ↗

Financial reports

No financial reports recorded.